Related Experiment Video
Updated: Jul 16, 2025
07:29
Dosage-Adjusted Resistance Training in Mice with a Reduced Risk of Muscle Damage
Published on: August 31, 2022
1.8K
Current clinical application of dantrolene sodium
Hong Seuk Yang1, Jae Moon Choi2, Junyong In3
1Department of Anesthesiology and Pain Medicine, Daejeon Eulji Medical Center, Eulji University, School of Medicine, Daejeon, Korea.
Anesthesia and Pain Medicine
|September 11, 2023
Summary
Dantrolene sodium effectively manages malignant hyperthermia by suppressing calcium release from ryanodine receptors. A new hydrophilic formulation may improve intravenous administration for this life-threatening condition.
Area of Science:
- Pharmacology
- Anesthesiology
- Biochemistry
Background:
- Dantrolene sodium (DS) was initially an oral antispasmodic.
- It became the primary treatment for malignant hyperthermia (MH) in 1975 via intravenous administration.
- Intravenous DS administration for MH can be challenging.
Purpose of the Study:
- To review the pharmacological properties of dantrolene sodium.
- To discuss its applications, contraindications, adverse effects, and drug interactions.
- To highlight recent advancements in DS formulation.
Main Methods:
- Literature review of reference articles.
- Analysis of pharmacological data on dantrolene sodium.
- Examination of ryanodine receptor (RyR) function.
Main Results:
- DS suppresses Ca2+ release from ryanodine receptors (RyRs).
- RyRs are implicated in MH and other diseases like cardiac arrhythmias and Alzheimer's.
- A new hydrophilic formulation of DS has been developed.
Conclusions:
- Anesthesiologists must understand DS pharmacology for MH management.
- DS has potential therapeutic applications beyond MH due to its effect on RyRs.
- Recent formulation improvements may address administration challenges.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
703
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
703
01:31Skeletal Muscle Relaxants: Therapeutic Uses
511
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
511
01:21Skeletal Muscle Relaxants: Adverse Effects
398
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
398
01:26Heart Failure Drugs: Inotropic Agents
617
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
617
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
455
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
455